Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 8Unknown 7Terminated 3Completed 2Suspended 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Noonan Syndrome 5 1

Interventions

pembrolizumab 438Carboplatin 322Nivolumab 286Cyclophosphamide 280Specimen Handling 257Cisplatin 252Paclitaxel 249Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 167atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 113Oxaliplatin 112Etoposide 111Radiosurgery 109venetoclax 108Fluorouracil 108fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Antineoplastic Agents × Clear all
NCT05566795 2026-05-14

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Day One Biopharmaceuticals, Inc.

Phase 3 Active not recruiting
418 enrolled

Noonan Syndrome 5

Data powered by HemOnc (CC BY 4.0) Colophon âš¡